NCT01491607View on ClinicalTrials.gov

Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Anthrax
Interventions
BIOLOGICAL

BioThrax

BioThrax, 0.5 mL administered subcutaneously on days 0, 14, and 28.

Trial Locations (4)

14609

Rochester Clinical Research, Rochester

29464

Coastal Carolina Research Center, Mt. Pleasant

33143

Miami Research Associates, Miami

84124

Jean Brown Research, Salt Lake City

Sponsors
All Listed Sponsors
collaborator

Department of Health and Human Services

FED

lead

Emergent BioSolutions

INDUSTRY